Bio-Techne (TECH) Competitors

$44.74 -0.15 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$45.61 +0.87 (+1.94%)

As of 05:09 PM Eastern

TECH vs. BRKR, A, BIO, CRL, and DHR

Should you buy Bio-Techne stock or one of its competitors? MarketBeat compares Bio-Techne with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Techne include Bruker (BRKR), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Danaher (DHR).

How does Bio-Techne compare to Bruker?

Bruker (NASDAQ:BRKR) and Bio-Techne (NASDAQ:TECH) are both mid-cap life sciences tools & services companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

In the previous week, Bio-Techne had 5 more articles in the media than Bruker. MarketBeat recorded 15 mentions for Bio-Techne and 10 mentions for Bruker. Bruker's average media sentiment score of 0.66 beat Bio-Techne's score of 0.23 indicating that Bruker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bio-Techne has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.46B	1.94	-$8.60M	-$0.24	N/A
Bio-Techne	$1.21B	5.79	$73.40M	$0.69	64.84

Bruker has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.5%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.7%. Bruker pays out -83.3% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

79.5% of Bruker shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bio-Techne has a net margin of 9.05% compared to Bruker's net margin of -0.65%. Bio-Techne's return on equity of 13.57% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-0.65%	11.60%	4.25%
Bio-Techne	9.05%	13.57%	10.66%

Bruker presently has a consensus target price of $50.54, indicating a potential upside of 14.44%. Bio-Techne has a consensus target price of $66.77, indicating a potential upside of 49.24%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Techne is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Bio-Techne beats Bruker on 14 of the 18 factors compared between the two stocks.

How does Bio-Techne compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

In the previous week, Bio-Techne had 8 more articles in the media than Agilent Technologies. MarketBeat recorded 15 mentions for Bio-Techne and 7 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 0.83 beat Bio-Techne's score of 0.23 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$7.07B	4.53	$1.30B	$4.53	24.99
Bio-Techne	$1.21B	5.79	$73.40M	$0.69	64.84

Agilent Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.9%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.7%. Agilent Technologies pays out 22.5% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

87.4% of Agilent Technologies shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 0.2% of Agilent Technologies shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Agilent Technologies has a net margin of 18.26% compared to Bio-Techne's net margin of 9.05%. Agilent Technologies' return on equity of 24.49% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	18.26%	24.49%	12.83%
Bio-Techne	9.05%	13.57%	10.66%

Agilent Technologies presently has a consensus target price of $163.71, indicating a potential upside of 44.59%. Bio-Techne has a consensus target price of $66.77, indicating a potential upside of 49.24%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Agilent Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Agilent Technologies beats Bio-Techne on 13 of the 20 factors compared between the two stocks.

How does Bio-Techne compare to Bio-Rad Laboratories?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Bio-Techne has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.21B	5.79	$73.40M	$0.69	64.84
Bio-Rad Laboratories	$2.58B	2.55	$759.90M	$6.07	40.51

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 6.52%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Bio-Rad Laboratories	6.52%	3.56%	2.49%

Bio-Techne currently has a consensus target price of $66.77, indicating a potential upside of 49.24%. Bio-Rad Laboratories has a consensus target price of $333.00, indicating a potential upside of 35.43%. Given Bio-Techne's stronger consensus rating and higher probable upside, research analysts plainly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bio-Techne had 14 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 15 mentions for Bio-Techne and 1 mentions for Bio-Rad Laboratories. Bio-Techne's average media sentiment score of 0.23 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Bio-Techne beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.

How does Bio-Techne compare to Charles River Laboratories International?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Bio-Techne has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.21B	5.79	$73.40M	$0.69	64.84
Charles River Laboratories International	$4.03B	1.90	-$144.34M	-$3.76	N/A

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Bio-Techne currently has a consensus target price of $66.77, indicating a potential upside of 49.24%. Charles River Laboratories International has a consensus target price of $205.86, indicating a potential upside of 29.44%. Given Bio-Techne's stronger consensus rating and higher probable upside, research analysts plainly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Bio-Techne had 7 more articles in the media than Charles River Laboratories International. MarketBeat recorded 15 mentions for Bio-Techne and 8 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.55 beat Bio-Techne's score of 0.23 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Bio-Techne beats Charles River Laboratories International on 11 of the 16 factors compared between the two stocks.

How does Bio-Techne compare to Danaher?

Danaher (NYSE:DHR) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Danaher currently has a consensus target price of $240.70, indicating a potential upside of 46.24%. Bio-Techne has a consensus target price of $66.77, indicating a potential upside of 49.24%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Danaher.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.86
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

79.1% of Danaher shares are held by institutional investors. Comparatively, 98.9% of Bio-Techne shares are held by institutional investors. 10.8% of Danaher shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Danaher has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 1.0%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.7%. Danaher pays out 30.9% of its earnings in the form of a dividend. Bio-Techne pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.78B	4.70	$3.61B	$5.17	31.84
Bio-Techne	$1.21B	5.79	$73.40M	$0.69	64.84

Danaher has a net margin of 14.89% compared to Bio-Techne's net margin of 9.05%. Bio-Techne's return on equity of 13.57% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	14.89%	10.91%	6.94%
Bio-Techne	9.05%	13.57%	10.66%

In the previous week, Danaher had 3 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Danaher and 15 mentions for Bio-Techne. Danaher's average media sentiment score of 1.17 beat Bio-Techne's score of 0.23 indicating that Danaher is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	14 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Danaher beats Bio-Techne on 12 of the 20 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECH vs. The Competition

Export

Metric	Bio-Techne	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.00B	$3.40B	$6.29B	$12.46B
Dividend Yield	0.67%	2.31%	2.79%	5.30%
P/E Ratio	64.84	18.98	20.89	25.59
Price / Sales	5.79	176.16	522.17	62.83
Price / Cash	19.40	122.51	42.94	55.34
Price / Book	3.36	6.74	9.86	6.70
Net Income	$73.40M	$24.11M	$3.55B	$333.77M
7 Day Performance	-12.12%	0.06%	-0.32%	0.45%
1 Month Performance	-23.73%	0.81%	1.33%	4.06%
1 Year Performance	-6.52%	78.08%	41.10%	36.24%

Bio-Techne Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECH Bio-Techne	3.7472 of 5 stars	$44.74 -0.3%	$66.77 +49.2%	-13.0%	$7.00B	$1.21B	64.84	3,100	Dividend Announcement
BRKR Bruker	3.0268 of 5 stars	$36.39 -1.1%	$49.38 +35.7%	+13.2%	$5.60B	$3.44B	N/A	11,085	Analyst Downgrade
A Agilent Technologies	4.8896 of 5 stars	$112.15 -2.1%	$163.71 +46.0%	-2.4%	$32.36B	$6.95B	24.76	18,100
BIO Bio-Rad Laboratories	2.203 of 5 stars	$257.80 +0.5%	$333.00 +29.2%	-3.5%	$6.92B	$2.58B	42.47	7,450
CRL Charles River Laboratories International	3.7361 of 5 stars	$172.10 +3.8%	$205.36 +19.3%	+12.6%	$8.18B	$4.02B	N/A	19,700	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECH) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Competitors

TECH vs. BRKR, A, BIO, CRL, and DHR

How does Bio-Techne compare to Bruker?

Summary

How does Bio-Techne compare to Agilent Technologies?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Summary

How does Bio-Techne compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Competitors

TECH vs. BRKR, A, BIO, CRL, and DHR

How does Bio-Techne compare to Bruker?

Does the media favor BRKR or TECH?

Which has stronger valuation & earnings, BRKR or TECH?

Which has more risk & volatility, BRKR or TECH?

Is BRKR or TECH a better dividend stock?

Do institutionals & insiders believe in BRKR or TECH?

Is BRKR or TECH more profitable?

Do analysts recommend BRKR or TECH?

Summary

How does Bio-Techne compare to Agilent Technologies?

Does the media favor A or TECH?

Which has stronger valuation & earnings, A or TECH?

Which has more risk & volatility, A or TECH?

Is A or TECH a better dividend stock?

Do institutionals & insiders believe in A or TECH?

Is A or TECH more profitable?

Do analysts recommend A or TECH?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Which has more risk and volatility, TECH or BIO?

Which has higher valuation & earnings, TECH or BIO?

Is TECH or BIO more profitable?

Do analysts rate TECH or BIO?

Does the media favor TECH or BIO?

Do insiders and institutionals have more ownership in TECH or BIO?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Which has more risk and volatility, TECH or CRL?

Which has higher valuation & earnings, TECH or CRL?

Is TECH or CRL more profitable?

Do analysts rate TECH or CRL?

Does the media favor TECH or CRL?

Do insiders and institutionals have more ownership in TECH or CRL?

Summary

How does Bio-Techne compare to Danaher?

Do analysts rate DHR or TECH?

Do institutionals & insiders hold more shares of DHR or TECH?

Which has more risk & volatility, DHR or TECH?

Is DHR or TECH a better dividend stock?

Which has higher earnings & valuation, DHR or TECH?

Is DHR or TECH more profitable?

Does the media refer more to DHR or TECH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools